

---

ongoing trials - trial from [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

## **Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis - - RECRUITING**

**Code:** NCT06429176    **Year:** 2024    **Date:** 2024

**Author:**

### **Participants**

adult patients with cystic fibrosis (CF). -

### **Interventions**

multiple doses of the study drug, SPL84drug SPL84 or a placebo by inhalation every week for 9 weeks months

### **Outcome measures**

Safety and effectiveness. Patients will Visit the clinic approximately 14 times over 17.5 weeks for checkups and tests". Number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs), Incidence, nature, and severity of AEs and SAEs, Day 1 through Day 87

<https://clinicaltrials.gov/study/NCT06429176>

### **Keywords**

SPL84; Respiratory System Agents; pharmacological\_intervention;